Abciximab treatment during primary PTCA can be associated with rapid-onset severe thrombocytopenia and fatal cerebral hemorrhage.
Answers are grounded in this paper and cite their sources.
Alerts to rapid fatal hemorrhage risk with abciximab; leaves open optimal monitoring or prevention in primary PTCA.
We describe the case of a fatal cerebral hemorrhage associated with a severe thrombocytopenia (4.0 x 10(9)/l), occurring only 90 min after starting treatment with abciximab, in a patient undergoing primary percutaneous transluminal coronary angioplasty (PTCA) for an acute myocardial infarction. Cathet. Cardiovasc. Intervent. 49:177-180, 2000.
No takes yet. Share an insight, caveat, or question.
Vahdat et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: